Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| IPSEN | 6 | 14 | -0,29 % | ||
| VALLOUREC | 4 | 4 | +1,04 % | ||
| ATOS | 3 | 12 | -0,96 % | ||
| AMUNDI | 3 | 3 | +0,22 % | ||
| JCDECAUX | 2 | 8 | -1,10 % | ||
| ERAMET | 2 | 4 | 0,00 % | ||
| LA FRANCAISE DES JEUX | 2 | 4 | -0,62 % | ||
| NEXANS | 1 | 5 | -0,09 % | ||
| IPSOS | 1 | 5 | -0,26 % | ||
| AEROPORTS DE PARIS | 1 | 4 | -0,41 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Earnings call: Groupe ADP reports steady growth and strategic advances in H1 2024 | 1 | Investing.com | ||
| Fr | Earnings call: Ipsos reports steady growth with cautious outlook for 2024 | 1 | Investing.com | ||
| Fr | Earnings call: JCDecaux sees robust H1 2024 growth amid digital push | 1 | Investing.com | ||
| Fr | emeis: Growth in Revenue in First-Half 2024 at €2,772 Million (Up 9.2%) | 246 | Business Wire | Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240726471228/en/
emeis (Paris:EMEIS):
Growth in revenue in first-half... ► Artikel lesen | |
| Fr | Earnings call: Nexans posts robust H1 2024 financials, upgrades outlook | 1 | Investing.com | ||
| Fr | JCDecaux: Half-year financial report 2024 | 1 | GlobeNewswire (USA) | ||
| Fr | Vallourec: availability of the Interim Financial Report (half-year ended 30 June 2024) | 176 | GlobeNewswire (Europe) | Vallourec: availability of the Interim Financial Report(half-year ended 30 June 2024)
Meudon (France), July 26th 2024 - The Vallourec Interim financial report ended 30 June 2024 has been made available... ► Artikel lesen | |
| Fr | Sopra Steria Group: 2024 Half-Year Financial Report Now Available | 143 | Business Wire | Regulatory News:
Sopra Steria (Paris:SOP) announces today that they have made available to the public and filed with the Autorité des Marchés Financiers (AMF) the half-yearly Financial Report at... ► Artikel lesen | |
| Fr | Ipsen liver disease drugs endorsed in EU | 1 | Seeking Alpha | ||
| Fr | Saleh geht - Mustier übernimmt: Atos verschleißt den nächsten CEO | 34 | COMPUTERWOCHE | ||
| Fr | Europe's CHMP endorses clutch of new medicines, including Astellas, J&J and Ipsen offerings | 4 | FiercePharma | ||
| Fr | Vicat reports growth in first-half financial results | 1 | Global Cement | ||
| Fr | Vallourec S.A. reports Q2 results | 2 | Seeking Alpha | ||
| Fr | Ipsen Gets CHMP Positive Opinions For Iqirvo, Kayfanda | - | RTTNews | ||
| Fr | Ipsen gains ex-US rights to Day One's brain cancer therapy in deal worth over $460m | 1 | PMLiVE | ||
| Fr | GENFIT S.A.: Positive Opinion from EMA Committee for Ipsen's Iqirvo (elafibranor) in Primary Biliary Cholangitis | 98 | GlobeNewswire (Europe) | Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the... ► Artikel lesen | |
| Fr | Digital customer and revenue growth helps FDJ revenue hit €1.42bn in H1 | 2 | iGaming Business | ||
| Fr | Ipsen Pharma: Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases | 160 | GlobeNewswire (Europe) | Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
CHMP positive... ► Artikel lesen | |
| Fr | ERAMET reports 1H results | 4 | Seeking Alpha | ||
| Fr | Jean Pierre Mustier: Atos ernennt nächsten CEO | 45 | Netzwoche |
Seite:
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
